Dudediligence.

Matinas BioPharma Holdings, Inc

MTNBAMEX · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Net income, by quarter
−$4.3MSep ’24−$8.4MDec ’24−$1.7MMar ’25−$5.2MJun ’25−$1.5MSep ’25−$1.9MDec ’25−$1.9MMar ’26−$1.3MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$33,000$3.2M$1.1Mnone on filenone on file
Operating income−$24.7M−$24.6M−$23.8M−$24.6M−$7.0M
Net income−$23.3M−$21.0M−$22.9M−$24.3M−$10.3M
Operating cash flow−$15.2M−$19.2M−$15.3M−$15.9M−$7.0M
Free cash flow−$15.5M−$20.0M−$15.5Mnone on filenone on file
Cash$21.0M$6.8M$4.8M$7.3M$4.0M
Shares outstanding216.3M217.3M4.3M5.1M6.4M